Overview
DSGN market data
Price History
DSGN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.88 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.66 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,600.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $4.68 – $17.25 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $900.6M · P/B 2.51.
Company News
Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) EstimateBenzinga · Aug 3, 2026, 12:04 PM
8-K filing — Design Therapeutics, Inc. (DSGN)SEC EDGAR · Aug 3, 2026, 12:03 PM
Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy Type-1Benzinga · Jun 30, 2026, 12:10 PM
TAT Technologies Posts Upbeat Q1 Earnings, Joins Roivant Sciences, Immunitybio And Other Big Stocks Moving Higher On WednesdayBenzinga · May 20, 2026, 2:05 PM
Design Therapeutics Stock Wobbles After Rare Genetic Disease DataBenzinga · May 18, 2026, 6:30 PM
Crude Oil Gains Over 2%; US Homebuilder Sentiment Increases In MayBenzinga · May 18, 2026, 6:30 PM
Nasdaq Down 200 Points; Brady Earnings Top ViewsBenzinga · May 18, 2026, 4:25 PM
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich AtaxiaGlobenewswire Inc · May 18, 2026, 11:15 AM
Design Therapeutics Announces Biomarker And Clinical Data From Its Ongoing Phase 1/2 RESTORE-FA Trial Evaluating DT-216P2 In Patients With Friedreich Ataxia; Patients Demonstrated Improvements In The Modified Friedreich's Ataxia Rating Scale And In The Upright Stability ScoreBenzinga · May 18, 2026, 11:10 AM
Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care StockBenzinga · May 15, 2026, 11:50 AM